Conduit Pharmaceuticals Inc. (NASDAQ:CDT – Get Free Report) Director Andrew Regan sold 1,389,820 shares of the company’s stock in a transaction on Friday, July 12th. The stock was sold at an average price of $0.25, for a total transaction of $347,455.00. Following the sale, the director now directly owns 12,941,319 shares of the company’s stock, valued at $3,235,329.75. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Andrew Regan also recently made the following trade(s):
- On Wednesday, July 17th, Andrew Regan sold 1,514,100 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.26, for a total transaction of $393,666.00.
- On Monday, July 15th, Andrew Regan sold 1,005,200 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.25, for a total value of $251,300.00.
- On Wednesday, July 10th, Andrew Regan sold 150,000 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.33, for a total value of $49,500.00.
- On Monday, July 8th, Andrew Regan sold 35,923 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.51, for a total value of $18,320.73.
- On Wednesday, July 3rd, Andrew Regan sold 1,000 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.64, for a total value of $640.00.
Conduit Pharmaceuticals Stock Down 1.1 %
Shares of CDT traded down $0.00 during trading hours on Thursday, reaching $0.13. 1,313,045 shares of the company traded hands, compared to its average volume of 4,557,714. The stock’s fifty day moving average is $0.18 and its 200 day moving average is $1.80. Conduit Pharmaceuticals Inc. has a 1-year low of $0.11 and a 1-year high of $22.00.
Wall Street Analysts Forecast Growth
Separately, Berenberg Bank upgraded shares of Conduit Pharmaceuticals to a “strong-buy” rating in a research note on Friday, July 26th.
Get Our Latest Analysis on CDT
About Conduit Pharmaceuticals
Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
See Also
- Five stocks we like better than Conduit Pharmaceuticals
- What is the Nikkei 225 index?
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- What Are the FAANG Stocks and Are They Good Investments?
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Conduit Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conduit Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.